AstraZeneca and Organon have been found in serious breach of the U.K.’s pharma code, with a watchdog ruling both companies ...

Some four years into its run as an independent women’s health outfit, Organon is parting ways with its first CEO after an ...

An experimental GLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner Innovent has bested Novo Nordisk’s reigning GLP-1 semaglutide in a phase 3 study across both b | ...

More and more, as momentum builds for the soon-to-be-blockbuster Winrevair, Merck’s $11.5 billion buyout of Acceleron in 2021 is looking like a savvy move. | Paving the way for the label update were ...

To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy ...

On Friday, the FDA approved Bayer’s dual neurokinin (NK) targeted therapy elinzanetant, which will now be marketed in the U.S ...

Just as pharmaceutical tariff uncertainty seemed to be easing in the U.S., the Trump administration is reportedly staging a ...

Over the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the ...

With another quarter of growth in the books, Swiss CDMO Lonza is continuing to regain its forward momentum as it seeks to ...

Ipsen unveiled a new educational initiative dedicated to supporting teenagers and young adults in the transition from their ...

Dermatology specialist Galderma has hopped on the U.S. manufacturing bandwagon, revealing a commitment to spend more than ...

After clearing Novo Nordisk’s semaglutide treatments Ozempic and Wegovy to reduce the risk of major adverse cardiovascular ...